GlassScriptPhysician profile
Heidi L Gregg
NPI 1801165006
$6,618.45
in general payments reported to CMS, 2019-2025
29 companies · $2,637 in 2025
The $2,637 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.68 · 2022: $54.36 · 2023: $876 · 2024: $2,988 · 2025: $2,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,187 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,187.49 |
| Education | $313.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,610.15 | 2023-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,211.10 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $645.64 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $554.20 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $491.57 | 2021-2025 | Dupixent |
| Verona Pharma, INC. | $305.61 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $280.50 | 2024-2025 | Glassia |
| Mylan Specialty L.P. | $191.37 | 2023-2024 | Yupelri, Yupelri |
| Electromed, INC. | $139.88 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.33 | 2023-2025 | Ofev |
| Insmed, INC. | $104.02 | 2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $101.20 | 2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $88.10 | 2024-2025 | Lumryz |
| Philips North America LLC | $86.41 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $81.77 | 2024-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $75.05 | 2023-2025 | Winrevair, Dificid |
| Inspire Medical Systems, INC. | $67.79 | 2024 | Inspire |
| Ambu INC. | $65.89 | 2025 | |
| Pfizer INC. | $60.99 | 2023-2024 | |
| Genentech USA, INC. | $45.26 | 2023 | Xolair |
| Amgen INC. | $36.70 | 2025 | Tezspire |
| Vifor Pharma, INC. | $30.07 | 2025 | Zemaira |
| Baxter Healthcare | $26.53 | 2024 | Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $25.79 | 2024 | |
| United Therapeutics Corporation | $21.97 | 2025 | Tyvaso |
| Medtronic, INC. | $21.93 | 2022 | |
| Alk-Abello, INC | $18.68 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.96 | 2024-2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Gregg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.